Fatty acid-binding protein 4: a key regulator of ketoacidosis in new-onset type 1 diabetes.
Animals
Blood Glucose
/ metabolism
Child
Diabetes Mellitus, Experimental
Diabetes Mellitus, Type 1
/ metabolism
Diabetic Ketoacidosis
/ metabolism
Fatty Acid-Binding Proteins
/ physiology
Female
Glycated Hemoglobin
/ metabolism
Humans
Insulin
/ blood
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Prospective Studies
Adipokine
DKA
FABP4
Fatty acid-binding protein
Ketogenesis
Type 1 diabetes
aP2
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
21
06
2021
accepted:
06
09
2021
pubmed:
23
11
2021
medline:
26
3
2022
entrez:
22
11
2021
Statut:
ppublish
Résumé
Fatty acid-binding protein 4 (FABP4) is an adipokine with a key regulatory role in glucose and lipid metabolism. We prospectively evaluated the role of FABP4 in the pathophysiology of diabetic ketoacidosis (DKA) in new-onset type 1 diabetes. Clinical and laboratory data were prospectively collected from consecutive children presenting with new-onset type 1 diabetes. In addition to blood chemistry and gases, insulin, C-peptide, serum FABP4 and NEFA were collected upon presentation and 48 h after initiation of insulin treatment. In a mouse model of type 1 diabetes, glucose, insulin, β-hydroxybutyrate and weight were compared between FABP4 knockout (Fabp4 Included were 33 children (mean age 9.3 ± 3.5 years, 52% male), of whom 14 (42%) presented with DKA. FABP4 levels were higher in the DKA group compared with the non-DKA group (median [IQR] 10.1 [7.9-14.2] ng/ml vs 6.3 [3.9-7] ng/ml, respectively; p = 0.005). The FABP4 level was positively correlated with HbA FABP4 is suggested to be a necessary regulator of ketogenesis in insulin-deficient states.
Identifiants
pubmed: 34806114
doi: 10.1007/s00125-021-05606-0
pii: 10.1007/s00125-021-05606-0
doi:
Substances chimiques
Blood Glucose
0
FABP4 protein, human
0
Fabp4 protein, mouse
0
Fatty Acid-Binding Proteins
0
Glycated Hemoglobin A
0
Insulin
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
366-374Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7(6):489–503. https://doi.org/10.1038/nrd2589
doi: 10.1038/nrd2589
pubmed: 18511927
pmcid: 2821027
Hotamisligil GS, Bernlohr DA (2015) Metabolic functions of FABPs - mechanisms and therapeutic implications. Nat Rev Endocrinol 11:592–605. https://doi.org/10.1038/nrendo.2015.122
doi: 10.1038/nrendo.2015.122
pubmed: 26260145
pmcid: 26260145
Ertunc ME, Sikkeland J, Fenaroli F et al (2015) Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity. J Lipid Res 56(2):423–434. https://doi.org/10.1194/jlr.M055798
doi: 10.1194/jlr.M055798
pubmed: 25535287
pmcid: 4306695
Mita T, Furuhashi M, Hiramitsu S et al (2015) FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Silver Spring) 23(2):359–367. https://doi.org/10.1002/oby.20954
doi: 10.1002/oby.20954
Syamsunarno MRAA, Iso T, Hanaoka H et al (2013) A critical role of fatty acid binding protein 4 and 5 (FABP4/5) in the systemic response to fasting. PLoS One 8(11):e79386. https://doi.org/10.1371/journal.pone.0079386
doi: 10.1371/journal.pone.0079386
pubmed: 24244493
pmcid: 3828394
Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274(5291):1377–1379. https://doi.org/10.1126/science.274.5291.1377
doi: 10.1126/science.274.5291.1377
pubmed: 8910278
Cao H, Sekiya M, Ertunc ME et al (2013) Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 17(5):768–778. https://doi.org/10.1016/j.cmet.2013.04.012
doi: 10.1016/j.cmet.2013.04.012
pubmed: 23663740
pmcid: 3755450
Kralisch S, Fasshauer M (2013) Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 56(1):10–21. https://doi.org/10.1007/s00125-012-2737-4
doi: 10.1007/s00125-012-2737-4
pubmed: 23052058
pmcid: 23052058
Liu H, Guo M, Jiang F-L (2018) Serum concentrations of fatty acid-binding protein 4 in Chinese children with type 1 diabetes mellitus. J Diabetes Complicat 32(5):488–491. https://doi.org/10.1016/j.jdiacomp.2017.12.009
doi: 10.1016/j.jdiacomp.2017.12.009
Furuhashi M (2019) Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. J Atheroscler Thromb 26(3):216–232. https://doi.org/10.5551/jat.48710
doi: 10.5551/jat.48710
pubmed: 30726793
pmcid: 30726793
Wotherspoon AC, Young IS, McCance DR et al (2016) Serum fatty acid binding protein 4 (FABP4) predicts pre-eclampsia in women with type 1 diabetes. Diabetes Care 39(10):1827–1829. https://doi.org/10.2337/dc16-0803
doi: 10.2337/dc16-0803
pubmed: 27630211
Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373(9680):2027–2033. https://doi.org/10.1016/S0140-6736(09)60568-7
doi: 10.1016/S0140-6736(09)60568-7
pubmed: 19481249
Dabelea D, Mayer-Davis EJ, Saydah S et al (2014) Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 311(17):1778. https://doi.org/10.1001/jama.2014.3201
doi: 10.1001/jama.2014.3201
pubmed: 24794371
pmcid: 4368900
Große J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U (2018) Incidence of diabetic ketoacidosis of new-onset type 1 diabetes in children and adolescents in different countries correlates with human development index (HDI): an updated systematic review, Meta-analysis, and Meta-regression. Horm Metab Res 50(03):209–222. https://doi.org/10.1055/s-0044-102090
doi: 10.1055/s-0044-102090
pubmed: 29523007
Usher-Smith JA, Thompson M, Ercole A, Walter FM (2012) Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: a systematic review. Diabetologia 55(11):2878–2894. https://doi.org/10.1007/s00125-012-2690-2
doi: 10.1007/s00125-012-2690-2
pubmed: 22933123
pmcid: 3464389
Scibilia J, Finegold D, Dorman J, Becker D, Drash A (1986) Why do children with diabetes die? Acta Endocrinol Suppl (Copenh) 279:326–333
doi: 10.1530/acta.0.112S326
Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ (2010) Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes 59(12):3216–3222. https://doi.org/10.2337/db10-0862
doi: 10.2337/db10-0862
pubmed: 20739685
pmcid: 2992785
Wolfsdorf J, Glaser N, Sperling MA (2006) Diabetic ketoacidosis in infants, children, and adolescents: a consensus statement from the American Diabetes Association. Diabetes Care 29(5):1150–1159. https://doi.org/10.2337/diacare.2951150
doi: 10.2337/diacare.2951150
pubmed: 16644656
Goldstein A, Haelyon U, Krolik E, Sack J (2001) Comparison of body weight and height of Israeli schoolchildren with the Tanner and Centers for Disease Control and Prevention growth charts. Pediatrics 108(6):E108. https://doi.org/10.1542/peds.108.6.e108
doi: 10.1542/peds.108.6.e108
pubmed: 11731635
Wu KK, Huan Y (2008) Streptozotocin-Induced Diabetic Models in Mice and Rats. In: Current Protocols in Pharmacology. John Wiley & Sons, Inc., Hoboken, NJ, USA, p Unit 5.47
Xu A, Wang Y, Xu JY et al (2006) Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52(3):405–413. https://doi.org/10.1373/clinchem.2005.062463
doi: 10.1373/clinchem.2005.062463
pubmed: 16423904
Aeberli I, Beljean N, Lehmann R, l’Allemand D, Spinas GA, Zimmermann MB (2008) The increase of fatty acid-binding protein aP2 in overweight and obese children: interactions with dietary fat and impact on measures of subclinical inflammation. Int J Obes 32(10):1513–1520. https://doi.org/10.1038/ijo.2008.128
doi: 10.1038/ijo.2008.128
Tirosh A, Calay ES, Tuncman G et al (2019) The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Transl Med 11(489):eaav0120. https://doi.org/10.1126/scitranslmed.aav0120
doi: 10.1126/scitranslmed.aav0120
pubmed: 31019023
Coe NR, Simpson MA, Bernlohr DA (1999) Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 40(5):967–972. https://doi.org/10.1016/S0022-2275(20)32133-7
doi: 10.1016/S0022-2275(20)32133-7
pubmed: 10224167
Scheja L, Makowski L, Uysal KT et al (1999) Altered insulin secretion associated with reduced lipolytic efficiency in aP2−/− mice. Diabetes 48(10):1987–1994. https://doi.org/10.2337/DIABETES.48.10.1987
doi: 10.2337/DIABETES.48.10.1987
pubmed: 10512363
Grabacka M, Pierzchalska M, Dean M, Reiss K (2016) Regulation of ketone body metabolism and the role of PPARα. Int J Mol Sci 17(12):2093–2116. https://doi.org/10.3390/IJMS17122093
doi: 10.3390/IJMS17122093
pmcid: 5187893
Furuhashi M, Fucho R, Görgün CZ, Tuncman G, Cao H, Hotamisligil GS (2008) Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 118(7):2640–2650. https://doi.org/10.1172/JCI34750
doi: 10.1172/JCI34750
pubmed: 18551191
pmcid: 2423863
Laffel L (1999) Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev 15(6):412–426. https://doi.org/10.1002/(sici)1520-7560(199911/12)15:6<412::aid-dmrr72>3.0.co;2-8
doi: 10.1002/(sici)1520-7560(199911/12)15:6<412::aid-dmrr72>3.0.co;2-8
pubmed: 10634967
Gruber N, Reichman B, Lerner-Geva L, Pinhas-Hamiel O (2015) Increased risk of severe diabetic ketoacidosis among Jewish ultra-orthodox children. Acta Diabetol 52(2):365–371. https://doi.org/10.1007/s00592-014-0653-4
doi: 10.1007/s00592-014-0653-4
pubmed: 25267080
Vicinanza A, Messaaoui A, Tenoutasse S, Dorchy H (2019) Diabetic ketoacidosis in children newly diagnosed with type 1 diabetes mellitus: role of demographic, clinical, and biochemical features along with genetic and immunological markers as risk factors. A 20-year experience in a tertiary Belgian center. Pediatr Diabetes 20(5):pedi.12864. https://doi.org/10.1111/pedi.12864
doi: 10.1111/pedi.12864
Kelsey MM, Zeitler PS (2016) Insulin resistance of puberty. Curr Diab Rep 16(7):64. https://doi.org/10.1007/s11892-016-0751-5
doi: 10.1007/s11892-016-0751-5
pubmed: 27179965